Compass Therapeutics (CMPX) Q3 2026 earnings review
Regulators ask Compass for another trial while losses nearly double
Compass Therapeutics, a developer of antibody cancer drugs, ran into a regulatory roadblock for its lead medicine while its spending rose. Operating losses widened 82% to $29 million as the company paid for drug manufacturing and commercial preparations for tovecimig, its treatment for bile duct cancer. Although chief executive Thomas Schuetz highlighted peer-reviewed data showing the drug shrank tumors, US regulators recommended an extra clinical trial proving patients live longer before the company files for approval.
| Operating loss | $28.8M +82% from a year ago |
|---|---|
| Loss per share | $0.15 $0.08 a year ago |
| Cash and marketable securities | $163M $180M last quarter |
| Cash runway outlook | Unchanged expected to fund operations into 2028 |
⚖️ Verdict: 🔴 Bearish
The story got worse because the Food and Drug Administration pushed back against a near-term approval filing for tovecimig. Even after researchers adjusted the trial data for control-group patients who switched onto the drug, the survival benefit was not statistically significant, and Compass dropped its prior year-end filing target. On the positive side, $163 million in cash still funds operations into 2028, and two earlier cancer antibodies remain on track for clinical readouts before year-end.
The question now is whether Compass can persuade regulators to accept its application without running a new multi-year survival trial. Either the agency agrees to review the drug based on tumor shrinkage and delayed disease progression, or the company must fund another study before launching. The outcome of upcoming meetings with the regulator will decide the path.
🐂 Bull Case
Tovecimig Shrinks Tumors and Delays Disease Progression
Tovecimig is Compass's lead experimental antibody, designed to block two proteins that help tumors grow blood vessels. Chief executive Thomas Schuetz said the full Phase 2/3 results in biliary tract cancer, a rare cancer of the bile ducts, highlight the strength of the drug's data after publication in the Journal of Clinical Oncology.
- Tumor shrinkage rate (objective response rate): 18.0% with tovecimig plus chemotherapy versus 5.3% with chemotherapy alone
- Time before tumors grew (median progression-free survival): 4.7 months versus 2.6 months, cutting progression risk by 56%
- Disease control rate: 62.2% of patients saw tumors shrink or stay stable, versus 36.8% on chemotherapy alone
- Median duration of response: 4.9 months for responding patients
These peer-reviewed numbers matter because they prove the drug is active in second-line patients who have few treatment choices. That clinical activity is also why independent doctors are now testing the drug in three outside trials covering first-line bile duct cancer, colorectal cancer, and brain cancer.
What to watch: the company's planned Phase 2 basket study in other tumors with high DLL4 protein levels. Starting that trial will show whether Compass is ready to invest fresh capital into expanding tovecimig beyond bile duct cancer.
Three Earlier Cancer Antibodies Advance Toward Readouts
Beyond its lead drug, the Boston biotech is testing three other antibody therapies in early human trials. Management plans to share clinical updates later this year for both CTX-8371, an immunotherapy targeting two immune checkpoints, and CTX-10726, which pairs immune activation with blood-vessel blockade.
In lab studies presented at a medical meeting, CTX-10726 stripped PD-1 proteins off immune cells, "effectively turning PD1-positive cells into PD1-negative cells in the presence of VEGF", Schuetz said. Meanwhile, CTX-8371 is enrolling 68 patients across lung, breast, and lymphoma cohorts, and a third drug, CTX-471, is starting a Phase 2 trial for 36 neuroendocrine tumor patients.
What to watch: initial clinical data from the CTX-8371 expansion cohorts and the CTX-10726 dose-escalation study before year-end. Strong response rates in either update would give the pipeline a second anchor while tovecimig faces regulatory delays.
🐻 Bear Case
FDA Recommends Another Trial Before Tovecimig Filing
"The third quarter was a period of sustained execution across our pipeline," Schuetz said, adding that the team continues to prepare an approval application for tovecimig. A biologics license application (BLA) is the formal request asking US regulators to approve a biologic drug for sale.
However, in September the Food and Drug Administration (FDA) recommended "an additional study demonstrating a survival benefit before submission of a BLA". Compass disagrees, arguing a new trial is unnecessary given its existing data and the "urgent unmet medical need for patients with BTC".
This regulatory pushback matters because the company previously aimed to file for approval before the end of 2026. The current release drops that year-end timeline, and running another survival trial would add years and tens of millions of dollars before any commercial sales begin.
What to watch: the outcome of Compass's upcoming meetings with the FDA to define the filing path. If regulators insist on a new trial before accepting an application, commercial launch plans will face a multi-year delay.
Crossover-Adjusted Analysis Still Misses Survival Significance
In cancer drug approvals, overall survival—how long patients live after starting treatment—is the gold standard for regulators. In the Phase 2/3 bile duct cancer study, overall survival was "confounded by the high rate of crossover and no statistically significant difference in OS was observed", the company said.
Crossover happened because patients in the chemotherapy-only control group switched over to take tovecimig after their tumors grew. To estimate what survival would have looked like without those switches, researchers published a statistical adjustment called a Two-Stage Estimation in the Journal of Clinical Oncology.
Even with that adjustment, the survival hazard ratio was 0.85 with a p-value of 0.53, well above the 0.05 threshold needed to prove a statistically significant benefit. Because the statistical fix still did not prove patients lived longer, persuading the FDA to waive an extra survival trial will be difficult.
What to watch: whether the FDA accepts the 56% reduction in disease progression risk as enough for accelerated approval. A refusal would confirm that the weak survival statistic blocks a near-term filing.
Tovecimig Manufacturing Drives Operating Loss Up 82%
Compass has no approved drugs on the market and generates no revenue, so every dollar spent on drug production and launch preparation widens its losses. In the third quarter, the operating loss rose 82.1% from a year ago to $28.8 million, while net loss per share nearly doubled from $0.08 to $0.15.
Research and development expenses jumped 71.8% to $22.0 million because the company spent $8.6 million manufacturing batches of tovecimig. General and administrative overhead more than doubled to $6.8 million, lifted by $1.8 million in higher employee stock compensation and $1.5 million in pre-commercialization spending.
Spending heavily on commercial drug supply and launch preparations creates a financial mismatch now that the FDA wants another clinical trial before filing. If the filing is delayed, the company is burning cash on commercial readiness long before it can sell the drug.
What to watch: fourth-quarter pre-commercialization and manufacturing expenses. A drop in those costs would show management is conserving cash while it sorts out the regulatory delay.
👓 Other Themes
Cash Buffer Covers Over Two Years of Spending
Compass ended September with $163.1 million in cash and marketable securities, down from $208.9 million at the end of 2025, and carries no bank debt. Operations used $48 million of cash over the first nine months of 2026, which puts third-quarter operating cash burn at $16 million by our math and gives the company about 10 quarters of funding at the current pace.
💲 Other KPIs
Short-term bills owed by the company rose 74.5% from $14.0 million at the end of 2025, by our math. Accounts payable—money owed to suppliers and contractors—nearly quadrupled to $6.3 million, while accrued expenses rose to $16.4 million. Delaying those cash payments helped keep third-quarter operating cash burn lower than the $28.8 million operating loss.
The average number of shares rose 10.7% from 168.8 million a year ago by our math, reflecting the August 2025 stock offering that raised $129 million in net proceeds. Compared with the second quarter of 2026, the share count was unchanged at 186.8 million, so shareholders saw no new dilution during the summer.
Interest earned on cash and marketable securities rose 4.6% from a year ago by our math, but fell 10.7% from $1.8 million in the second quarter. As the biotech spends down its cash reserves to fund clinical trials and manufacturing, quarterly interest income will continue to shrink, slightly widening the net loss.
🔮 Guidance
Unchanged. Management still expects its $163.1 million in cash and marketable securities to fund operations into 2028. By our math, operations burned $16 million in the third quarter after using $32 million in the first half of the year, leaving more than five quarters of cash before 2028 begins.
Unchanged. The company still plans to release clinical data from the CTX-8371 cohort expansions in breast, lung, and lymphoma cancers, alongside dose-escalation updates for CTX-10726, before the end of 2026.
New. "Initial data from the first stage of the study are expected in the second half of 2027", Compass said, setting the first readout target for the 36-patient trial in neuroendocrine tumors.
❓ Key Questions
What happened to the year-end tovecimig filing target?
In the second quarter, management pointed to a potential approval filing prior to year-end 2026. The third-quarter release drops any target date. Investors need to know when the next FDA meeting takes place and whether a 2027 filing is still possible without a new trial.
Will Compass slow pre-commercial spending while addressing FDA feedback?
The company spent $4.6 million on pre-commercialization in the first nine months of 2026 and $11.1 million extra on tovecimig manufacturing. If the FDA requires a new survival study before filing, continuing to build commercial infrastructure now would burn cash years ahead of launch.
When will the Phase 2 DLL4 basket study start?
Earlier in 2026, management planned to start a Phase 2 basket trial of tovecimig across gastric, ovarian, renal, liver, and colorectal cancers following the bile duct cancer readout. The third-quarter update mentions evaluating new studies but gives no start date for the basket trial.
How many patients will the year-end pipeline updates include?
Compass promised clinical updates on both CTX-8371 and CTX-10726 before the end of 2026. For CTX-8371, which targets 68 patients across three tumor types at two dose levels, management has not said how many patients will have mature follow-up data this quarter.